BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
about
Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapyGain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug SensitivityForkhead Box C1 Regulates Human Primary Keratinocyte Terminal DifferentiationThe Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.A New Gene Expression Signature for Triple Negative Breast Cancer Using Frozen Fresh Tissue before Neoadjuvant Chemotherapy.Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis.Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development.FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer.GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer.FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression.Epithelial cell identity in hyperplastic precursors of breast cancer.Genetic suppression reveals DNA repair-independent antagonism between BRCA1 and COBRA1 in mammary gland development.BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers.An integrative transcriptomics approach identifies miR-503 as a candidate master regulator of the estrogen response in MCF-7 breast cancer cells.S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability.FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort.GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.BRCA1--conductor of the breast stem cell orchestra: the role of BRCA1 in mammary gland development and identification of cell of origin of BRCA1 mutant breast cancer.Combined Analysis of ChIP Sequencing and Gene Expression Dataset in Breast Cancer.The transcription factor GATA3 is required for homologous recombination repair by regulating CtIP expression.FOXC1: an emerging marker and therapeutic target for cancer.Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs).Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation.Prognostic impact of FOXP3 expression in triple-negative breast cancer.Racial disparity in breast cancer: can it be mattered for prognosis and therapy.FOXC1 in cancer development and therapy: deciphering its emerging and divergent roles.Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development.Research progress on the forkhead box C1.
P2860
Q28535227-166F3F4E-4648-4E36-8B3C-52BC51E36792Q28553888-CF9C3AFF-4B58-4C9E-904F-3A6ABD7FC0AEQ28941763-AF66F2E9-1BC3-4C66-BB76-0C8A49C03BC4Q30978083-490BB791-6EFA-49DD-A788-7EE50FDD305FQ33793872-8885D1B9-75E4-44A7-9FC3-FCFB10D6B955Q33850983-4B618836-7710-4686-BE97-A2327A9FABB8Q34391427-4FB8D2C1-A700-4786-B932-F3C8D03EBE6EQ34543873-B42B2551-C20B-4176-9C7E-367F355CD090Q34817460-4414E1AC-56D8-4340-B42B-CCC8D83B7F08Q35000662-25473E12-02EB-4B8B-B2D9-080BAD78AC8FQ35602325-B2BEE530-6F0D-41BA-9066-73F235636314Q36098052-BD0D776C-AB05-4C38-B66C-D61D6C82DA99Q36121103-0017D7F6-F663-4EAD-B43C-D83540C9BD1DQ36670266-39E9B138-3114-42E1-B42F-3876654CA6DEQ37224721-DB92FC96-C457-4130-9010-09DCA5E53510Q37268606-ACF9F219-5D25-42A5-9178-4614DF5E40ADQ37620665-816573F4-A091-4F4E-B3A7-23CB5381A137Q37689013-A3B2D62A-DE27-4AC1-BA92-F136A6C2A6B8Q37709554-647F7D97-422E-48ED-939F-732DE1E5A355Q37994602-60C35DC6-B1C6-428A-80DA-50BE9A7FA4E4Q38442565-53487390-5F56-44AC-B75F-BCCA2B727CE3Q38798176-94352C7C-9DAD-4CB6-B8B1-D93120B00022Q39176111-F84889D0-06C3-4A6E-B15A-7B44CF1C2B4AQ42317506-479F27E3-5B53-44DC-9328-81E0DDF289E0Q42509342-9426DA4B-9FFD-47B5-98EE-11BE4E22496FQ45809154-D81B1086-FA73-4A04-9C0F-0E3ACC37A9BDQ47692378-9D38FDD9-6CF6-4D22-929B-720F2C15AE05Q49624286-02A62AB8-CA38-492D-8E4D-741E33ED37F4Q49936294-B4F8500D-A089-447B-B4AC-F6B1DB117178Q53701147-FF8199F7-E15C-4949-A446-ACE598ED8E0C
P2860
BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
@en
BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
@nl
type
label
BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
@en
BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
@nl
prefLabel
BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
@en
BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
@nl
P2093
P2860
P356
P1433
P1476
BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers.
@en
P2093
D P Harkin
J J Gorski
N E Buckley
N T Crawford
P B Mullan
R D Kennedy
P2860
P2888
P304
P356
10.1038/ONC.2011.531
P407
P577
2011-11-28T00:00:00Z